<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03413956</url>
  </required_header>
  <id_info>
    <org_study_id>JS-LC-01</org_study_id>
    <nct_id>NCT03413956</nct_id>
  </id_info>
  <brief_title>An Observational Study to Explore Clinical Characteristics of the Patients With T1 Non-small Cell Lung Cancer</brief_title>
  <official_title>A Multi-centre Real-world Non-interventional Observational Study to Explore Clinical Characteristics of the Chinese Patients With T1 Non-small Cell Lung Cancer Complicated With Lymph Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Cancer Institute &amp; Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Cancer Institute &amp; Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The real-world observational study was designed to explore the odd factors of lymph
      metastases in the patients with T1 non-small cell lung cancer, the effects of clinical
      characteristics on lymph metastases, and compare the differences in lymph metastases in the
      subgroups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial is a multi-centre, real-world non-interventional observational study. In the study,
      the patients with T1 non-small cell lung cancer enrolled in clinics from 2015 to 2017 were
      included via a retrospectively review method and the study data on patient demographic/tumor
      biological characteristics, and clinical treatments were collected to explore the clinical
      odd factors of lymph metastases, evaluate the effects of clinical characteristics on lymph
      metastases, and compare the differences in lymph metastases in the subgroups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Actual">March 30, 2018</completion_date>
  <primary_completion_date type="Actual">March 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of the patients with lymph metastases</measure>
    <time_frame>2015 - 2017</time_frame>
    <description>Percentages of the patients with lymph metastases categorised by patient demographic and tumor biological characteristics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentages of N0/N1/N2/N3 patients</measure>
    <time_frame>2015 - 2017</time_frame>
    <description>Percentages of N0/N1/N2/N3 patients in the target population</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of N2 patients with lymph nodes</measure>
    <time_frame>2015 - 2017</time_frame>
    <description>Percentages of N2 patients with lymph nodes in N2 population</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of patients with lymph metastases categorised by tumor baseline characteristics</measure>
    <time_frame>2015 - 2017</time_frame>
    <description>Percentage of patients with lymph metastases categorised by tumor baseline characteristics</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of lymph nodes in N2 patients</measure>
    <time_frame>2015 - 2017</time_frame>
    <description>Number of lymph nodes in N2 patients categorised by tumor baseline characteristics</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of patients with N2 skip metastases</measure>
    <time_frame>2015 - 2017</time_frame>
    <description>Percentage of patients with N2 skip metastases categorised by tumor baseline characteristics</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">10885</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>NSCLC patients with lymph metastases</arm_group_label>
    <description>Pathologically diagnosed patients with T1 non-small cell lung cancer complicated with lymph metastases after surgeries</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgeries</intervention_name>
    <description>Surgeries</description>
    <arm_group_label>NSCLC patients with lymph metastases</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The eligible subjects are the Chinese T1 patients with non-small cell lung cancer
        complicated with lymph metastases
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who received surgeries from 2015 to 2017;

          -  Pathologically diagnosed patients with T1 non-small cell lung cancer;

        Exclusion Criteria:

        - Patients with tumor treatments (including chemotherapies, radiotherapies, biological
        therapies, intervention therapies)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Xu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jiangsu Cancer Institute and Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China People's Liberation Army Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan cancer hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital Affiliated to Tongji Medical College, Huaxi Technology University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Cancer Institute and Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xi'an Tangdu Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Hospital Affiliated to Medical College, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2018</study_first_submitted>
  <study_first_submitted_qc>January 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2018</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jiangsu Cancer Institute &amp; Hospital</investigator_affiliation>
    <investigator_full_name>Feng Jiang</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Chinese</keyword>
  <keyword>T1 non-small cell lung cancer</keyword>
  <keyword>Lymph metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

